|
End-of-day quote
Taiwan S.E.
30/10/2026
|
5-day change | 1st Jan Change | ||
| 33.55 TWD | -0.74% |
|
-0.30% | +0.45% |
| 09-23 | Cenra Names Chairman | MT |
| 08-14 | Cenra Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| Market Cap | 4.89B 150M 134M 123M 112M 209M 14.22B 213M 1.47B 591M 7.48B 562M 550M 23.6B | P/E 2024 |
15.1x | P/E 2025 | 14x |
|---|---|---|---|---|---|
| Enterprise Value | 7.14B 219M 196M 180M 163M 306M 20.79B 311M 2.15B 863M 10.94B 822M 804M 34.49B | EV / Sales 2024 |
0.9x | EV / Sales 2025 | 0.83x |
| Free-Float |
61.48% | Yield 2024 |
2.72% | Yield 2025 | 3.01% |
| 1 day | -0.74% | ||
| 1 week | -0.30% | ||
| 1 month | -1.32% | ||
| 3 months | +2.29% | ||
| 6 months | +5.84% | ||
| Current year | +0.45% |
| 1 week | 33.4 | 33.95 | |
| 1 month | 33.4 | 34.6 | |
| Current year | 31.55 | 37.65 | |
| 1 year | 31.55 | 37.65 | |
| 3 years | 29 | 44.55 | |
| 5 years | 29 | 44.55 | |
| 10 years | 29 | 44.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yi Chun Huang
DFI | Director of Finance/CFO | - | 07/03/2014 |
Yi Fen Chen
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hung Shou Chen
BRD | Director/Board Member | - | 27/05/2016 |
| Chairman | - | 05/11/2020 | |
Hou Jie Wang
BRD | Director/Board Member | - | 17/01/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.74% | -0.30% | -1.32% | - | 150M | ||
| +3.19% | +11.31% | +64.28% | +155.66% | 1,263B | ||
| -0.73% | +3.56% | +44.65% | +83.74% | 658B | ||
| +1.41% | +3.24% | +35.25% | +106.98% | 521B | ||
| +0.42% | +3.20% | +55.81% | +69.71% | 391B | ||
| +2.18% | +2.93% | +73.90% | +45.38% | 369B | ||
| +1.12% | +4.52% | +34.76% | +57.00% | 307B | ||
| +6.96% | +8.86% | +11.95% | +35.06% | 290B | ||
| +1.15% | +6.09% | +56.15% | +78.66% | 252B | ||
| +3.06% | +9.38% | +42.48% | +112.84% | 212B | ||
| Average | +1.80% | +5.28% | +41.79% | +82.78% | 426.21B | |
| Weighted average by Cap. | +2.01% | +6.60% | +50.51% | +99.19% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 8.92B 273M 245M 225M 204M 381M 25.95B 389M 2.69B 1.08B 13.65B 1.03B 1B 43.05B | 8.57B 263M 235M 216M 196M 366M 24.94B 373M 2.58B 1.04B 13.12B 986M 965M 41.37B |
| Net income | 317M 9.73M 8.71M 8.01M 7.26M 13.57M 923M 13.82M 95.55M 38.36M 486M 36.5M 35.72M 1.53B | 300M 9.2M 8.24M 7.58M 6.86M 12.83M 873M 13.07M 90.34M 36.27M 459M 34.51M 33.78M 1.45B |
| Net Debt | 2.46B 75.3M 67.44M 62.04M 56.21M 105M 7.15B 107M 740M 297M 3.76B 283M 277M 11.86B | 2.26B 69.16M 61.94M 56.97M 51.62M 96.49M 6.57B 98.3M 679M 273M 3.45B 260M 254M 10.89B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | NT$33.55 | -0.74% | 153,239 |
| 29/10/26 | NT$33.80 | -.--% | 73,535 |
| 28/10/26 | NT$33.80 | +0.30% | 76,329 |
- Stock Market
- Stocks
- 3716 Stock
Select your edition
All financial news and data tailored to specific country editions
















